Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones

被引:85
作者
Velezheva, Valeriya [1 ]
Brennan, Patrick [2 ]
Ivanov, Pavel [1 ]
Kornienko, Albert [1 ]
Lyubimov, Sergey [1 ]
Kazarian, Konstantin [3 ]
Nikonenko, Boris [3 ]
Majorov, Konstantin [3 ]
Apt, Alexander [3 ]
机构
[1] Russian Acad Sci, AN Nesmeyanov Inst Organoelement Cpds, 28 Vavilov Str, Moscow 117813, Russia
[2] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA
[3] Russian Acad Med Sci, Cent TB Res Inst, 2 Yauzskaya Alley, Moscow 107564, Russia
关键词
Anti-tuberculosis compounds; Indole-pyridine derived hydrazides; Hydrazide-hydrazones; Thiosemicarbazones; MYCOBACTERIUM-TUBERCULOSIS; DRUG DISCOVERY; ISONIAZID DERIVATIVES; BIOLOGICAL EVALUATION; ANTIMYCOBACTERIAL ACTIVITY; CHEMICAL-SYNTHESIS; INHIBITORS; DESIGN; TARGETS; AGENTS;
D O I
10.1016/j.bmcl.2015.12.049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We describe the design, synthesis, and in vitro antimycobacterial activity of a series of novel simple hybrid hydrazides and hydrazide-hydrazones combining indole and pyridine nuclei. The compounds are derivatives of 1-acetylindoxyl or substituted indole-3-carboxaldehydes tethered via a hydrazine group by simple CAN or double C=N bonds with 3-and 4-pyridines, 1-oxide 3-and 4-pyridine carbohydrazides. The most active of 15 compounds showed MICs values against an INH-sensitive strain of Mycobacterium tuberculosis H37Rv equal to that of INH (0.05-2 mu g/mL). Five compounds demonstrated appreciable activity against the INH-resistant M. tuberculosis CN-40 clinical isolate (MICs: 2-5 mu g/mL), providing justification for further in vivo studies. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 53 条
[1]  
Abdel-Magid Ahmed F, 2015, ACS Med Chem Lett, V6, P373, DOI 10.1021/acsmedchemlett.5b00080
[2]  
Anand N., 2015, CHEM BIOL INTERFACE, V5, P84
[3]  
[Anonymous], 2011, GLOB TUB CONTR
[4]  
Asif M, 2012, INT J PHARM CHEM, V2, P110
[5]   Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis [J].
Ballell, Lluis ;
Bates, Robert H. ;
Young, Rob J. ;
Alvarez-Gomez, Daniel ;
Alvarez-Ruiz, Emilio ;
Barroso, Vanessa ;
Blanco, Delia ;
Crespo, Benigno ;
Escribano, Jaime ;
Gonzalez, Ruben ;
Lozano, Sonia ;
Huss, Sophie ;
Santos-Villarejo, Angel ;
Julio Martin-Plaza, Jose ;
Mendoza, Alfonso ;
Jose Rebollo-Lopez, Maria ;
Remuinan-Blanco, Modesto ;
Luis Lavandera, Jose ;
Perez-Herran, Esther ;
Javier Gamo-Benito, Francisco ;
Francisco Garcia-Bustos, Jose ;
Barros, David ;
Castro, Julia P. ;
Cammack, Nicholas .
CHEMMEDCHEM, 2013, 8 (02) :313-321
[6]  
Belardinelli JM, 2013, EXPERT REV ANTI-INFE, V11, P429, DOI [10.1586/ERI.13.24, 10.1586/eri.13.24]
[7]  
Campos M. M., 2014, BMC P S4, V8, pO17
[8]   1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis [J].
Chatterji, Monalisa ;
Shandil, Radha ;
Manjunatha, M. R. ;
Solapure, Suresh ;
Ramachandran, Vasanthi ;
Kumar, Naveen ;
Saralaya, Ramanatha ;
Panduga, Vijender ;
Reddy, Jitendar ;
Prabhakar, K. R. ;
Sharma, Sreevalli ;
Sadler, Claire ;
Cooper, Christopher B. ;
Mdluli, Khisi ;
Iyer, Pravin S. ;
Narayanan, Shridhar ;
Shirude, Pravin S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) :5325-5331
[9]  
Cihan-Ustundag G., 2015, J ENZYME INHIB MED C
[10]   Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents [J].
Cihan-Ustundag, Gokce ;
Capan, Gultaze .
MOLECULAR DIVERSITY, 2012, 16 (03) :525-539